DelveInsight’s, “Sarcopenia Pipeline Insight 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sarcopenia pipeline landscape. It covers the Sarcopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Sarcopenia Research. Learn more about our innovative pipeline today! @ Sarcopenia Pipeline Outlook
Key Takeaways from the Sarcopenia Pipeline Report
- On 29 July 2025, Animuscure Inc. announced a clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
- DelveInsight’s Sarcopenia pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Sarcopenia treatment.
- The leading Sarcopenia Companies such as Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
- Promising Sarcopenia Pipeline Therapies such as AMC6156 0.1mg, Bimagrumab, MK-0773, REGN1033 (SAR391786), LPCN 1148, BIO101, Olimel N12, Glucose IV, Testosterone Enanthate, Finasteride, and others.
Stay informed about the cutting-edge advancements in Sarcopenia treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Sarcopenia Clinical Trials Assessment
Sarcopenia Emerging Drugs Profile
- BIO101: Biophytis
Sarconeos (BIO101) is a small molecule proto-oncogene protein c-mas-1 agonist that is administered orally. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility, and respiratory capacity in various age-related and muscular wasting conditions. The drug showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the product in the Phase II clinical trial study. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of Sarcopenia.
- MF-300: Epirium Bio
MF-300 is an orally bioavailable small molecule that reversibly binds to the Prostaglandin E2 (PGE2)-binding site of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme that converts PGE2 to an inactive metabolite. MF-300 target engagement inhibits 15-PGDH activity, stabilizing and increasing levels of PGE2 in a cell-based assay and in vivo in skeletal muscle in preclinical studies.
In humans and rodents, 15-PGDH gene expression is elevated in muscle coincident with the onset of age-induced muscle weakness. PGE2, a lipid signaling molecule with multiple beneficial effects on the motor unit, including enhanced muscle quality and improved function of the neuromuscular junction, is reduced in skeletal muscle of aged mice due to increased activity of 15-PGDH. Inhibiting 15-PGDH in aged muscle may be a strategy to increase physiologic levels of PGE2 to improve muscle quality and function. Currently, the drug is in the Phase I stage of its development for the treatment of Sacropenia.
- TRN005: Turn Biotechnologies
TRN-005 is a unique formulation to restore muscle mass and strength, and reverse age-related conditions that compromise people’s ability to lead active lifestyles. Preclinical results demonstrated improvement in stem cell growth and differentiation, acceleration of muscle recovery, increases in fiber thickness and force output. The drug is currently in Preclinical stage of development for the treatment of Sarcopenia.
The Sarcopenia Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcopenia Treatment.
- Sarcopenia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Sarcopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcopenia market.
Learn more about Sarcopenia Drugs opportunities in our groundbreaking Sarcopenia research and development projects @ Sarcopenia Unmet Needs
Sarcopenia Companies
Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Sarcopenia Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Sarcopenia Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Sarcopenia treatment by visiting our website. Stay informed about how we're transforming the future of Musculoskeletal @ Sarcopenia Market Drivers and Barriers, and Future Perspectives
Scope of the Sarcopenia Pipeline Report
- Coverage- Global
- Sarcopenia Companies- Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
- Sarcopenia Pipeline Therapies- AMC6156 0.1mg, Bimagrumab, MK-0773, REGN1033 (SAR391786), LPCN 1148, BIO101, Olimel N12, Glucose IV, Testosterone Enanthate, Finasteride, and others.
- Sarcopenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Sarcopenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Sarcopenia Pipeline on our website @ Sarcopenia Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Sarcopenia Overview
- Sarcopenia Pipeline Therapeutics
- Sarcopenia Therapeutic Assessment
- Sarcopenia – DelveInsight’s Analytical Perspective
- Mid Stage Sarcopenia Products (Phase II)
- BIO101: Biophytis
- Early Stage Sarcopenia Products (Phase I)
- MF-300: Epirium Bio
- Preclinical Stage Products
- TRN005: Turn Biotechnologies
- Inactive Sarcopenia Products
- Sarcopenia Companies
- Sarcopenia Key Products
- Sarcopenia Unmet Needs
- Sarcopenia Market Drivers and Barriers
- Sarcopenia- Future Perspectives and Conclusion
- Sarcopenia Analyst Views
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight
